Insider Selling: Liquidia Co. (NASDAQ:LQDA) CFO Sells 23,370 Shares of Stock

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 23,370 shares of the firm’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $275,298.60. Following the transaction, the chief financial officer now directly owns 401,755 shares of the company’s stock, valued at $4,732,673.90. This represents a 5.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Michael Kaseta also recently made the following trade(s):

• On Monday, December 2nd, Michael Kaseta sold 1,091 shares of Liquidia stock. The shares were sold at an average price of $11.51, for a total value of $12,557.41.

Liquidia Trading Up 6.9 %

Shares of Liquidia stock opened at $12.14 on Thursday. The stock has a 50-day moving average price of $11.23 and a 200 day moving average price of $11.02. The company has a market cap of $1.03 billion, a P/E ratio of -7.45 and a beta of 0.23. Liquidia Co. has a 1 year low of $8.26 and a 1 year high of $16.99.

Institutional Investors Weigh In On Liquidia

Hedge funds have recently bought and sold shares of the business. Quest Partners LLC purchased a new stake in Liquidia in the 2nd quarter worth about $27,000. Clear Harbor Asset Management LLC purchased a new stake in Liquidia in the 3rd quarter worth about $100,000. Signaturefd LLC raised its stake in shares of Liquidia by 38,400.0% during the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after purchasing an additional 9,984 shares in the last quarter. Ballentine Partners LLC purchased a new stake in shares of Liquidia during the 3rd quarter worth about $110,000. Finally, Whitcomb & Hess Inc. raised its stake in shares of Liquidia by 10.2% during the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after purchasing an additional 1,074 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on LQDA shares. Lifesci Capital started coverage on Liquidia in a research note on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price for the company. Scotiabank started coverage on Liquidia in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of Liquidia in a report on Thursday, January 9th. Wells Fargo & Company started coverage on Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $25.38.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).